8-K

Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 22, 2020

LAM RESEARCH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-12933	94-2634797
(State or Other Jurisdiction<br><br>of Incorporation)	(Commission<br><br>File Number)	(IRS Employer<br><br>Identification Number)

4650 Cushing Parkway

Fremont, California 94538

(Address of principal executive offices including zip code)

(510) 572-0200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share	LRCX	The Nasdaq Stock Market
		(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                      ☐

---

---

Table of Contents

Table of Contents

Item 2.02.	Results of Operations and Financial Condition	3
Item 8.01.	Other Events	3
Item 9.01.	Financial Statements and Exhibits	3
SIGNATURES		4
EX-99.1

---

Table of Contents

---

Item 2.02.	Results of Operations and Financial Condition

On April 22, 2020, Lam Research Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 29, 2020, the text of which is attached hereto as Exhibit 99.1.

The information in this item of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, the information in this item of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 8.01	Other Events

The Company is providing the disclosure below and supplementing the risk factors described in Item 1A Risk Factors of its Annual Report on Form 10-K for the fiscal year ended June 30, 2019 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended December 29, 2019 and September 29, 2019 (the "Periodic Reports") with the following risk factor. The information in this Current Report on Form 8-K, including the risk factor disclosure below, should be read in conjunction with the other risk factors described in the Periodic Reports.

The Recent COVID-19 Outbreak Has Adversely Impacted, and May Continue to Adversely Impact, Our Business, Operations, and Financial Results

The COVID-19 outbreak and efforts by national, state and local governments worldwide to control its spread have resulted in widespread measures aimed at containing the disease such as quarantines, travel bans, shutdowns, and shelter in place or “stay at home” orders, which collectively have significantly restricted the movement of people and goods and the ability of businesses to operate. These restrictions and measures, incidents of confirmed or suspected infections within our workforce or those of our suppliers or other business partners, and our efforts to act in the best interests of our employees, customers, and suppliers, have affected and are affecting our business and operations by, among other things, causing facility closures, production delays and capacity limitations; disrupting production by our supply chain; disrupting the transport of goods from our supply chain to us and from us to our customers; requiring modifications to our business processes; requiring the implementation of business continuity plans; requiring the development and qualification of alternative sources of supply; requiring the implementation of social distancing measures that require changes to existing manufacturing processes; disrupting business travel; disrupting our ability to staff our on-site manufacturing and research and development facilities; delaying capital expansion projects; and necessitating teleworking by a large proportion of our workforce.  These impacts have caused and are expected to continue to cause delays in product shipments and product development, increases in costs, and decreases in revenue, profitability and cash from operations, which have caused and are expected to cause an adverse effect on our results of operations that may be material.  The potential duration and impact of the outbreak on the global economy and on our business are difficult to predict and cannot be estimated with any degree of certainty, but the outbreak has resulted in significant disruption of global financial markets, increases in levels of unemployment, and economic uncertainty, which has adversely impacted our business and may continue to do so, and may lead to significant negative impacts on customer spending, demand for our products, the ability of our customers to pay, our financial condition and the financial condition of our suppliers, and our access to external sources of financing to fund our operations and capital expenditures.

Item 9.01.	Financial Statements and Exhibits

(d) Exhibits

99.1	Press Release dated April 22, 2020 announcing financial results for the fiscal quarter ended March 29, 2020

---

Table of Contents

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	April 22, 2020	LAM RESEARCH CORPORATION
		(Registrant)
		/s/ Douglas R. Bettinger
		Douglas R. Bettinger
		Executive Vice President, Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

		Exhibit

Exhibit 99.1

FOR IMMEDIATE RELEASE

Lam Research Corporation Reports Financial Results for the Quarter Ended March 29, 2020

FREMONT, Calif., April 22, 2020 - Lam Research Corporation (the "Company," "Lam," "Lam Research") today announced financial results for the quarter ended March 29, 2020 (the “March 2020 quarter”).

Highlights for the March 2020 quarter were as follows:

•	Revenue of $2.50 billion.
•	U.S. GAAP gross margin of 46.6%, U.S. GAAP operating income as a percentage of revenue of 27.7%, and U.S. GAAP diluted EPS of $3.88.
---	---
•	Non-GAAP gross margin of 46.3%, non-GAAP operating income as a percentage of revenue of 26.9%, and non-GAAP diluted EPS of $3.98.
---	---

Key Financial Data for the Quarters Ended

March 29, 2020 and December 29, 2019

(in thousands, except per-share data, percentages, and basis points)

U.S. GAAP
	March 2020			December 2019			Change Q/Q
Revenue	$	2,503,625		$	2,583,501		- 3%
Gross margin as percentage of revenue	46.6		%	45.7		%	+ 90 bps
Operating income as percentage of revenue	27.7		%	26.6		%	+ 110 bps
Diluted EPS	$	3.88		$	3.43		+ 13%
Non-GAAP
	March 2020			December 2019			Change Q/Q
Revenue	$	2,503,625		$	2,583,501		- 3%
Gross margin as percentage of revenue	46.3		%	45.7		%	+ 60 bps
Operating income as percentage of revenue	26.9		%	27.1		%	- 20 bps
Diluted EPS	$	3.98		$	4.01		- 1%

U.S. GAAP Financial Results

For the March 2020 quarter, revenue was $2,504 million, gross margin was $1,167 million, or 46.6% of revenue, operating expenses were $473 million, operating income was 27.7% of revenue, and net income was $575 million, or $3.88 per diluted share on a U.S. GAAP basis. This compares to revenue of $2,584 million, gross margin of $1,180 million, or 45.7% of revenue, operating expenses of $493 million, operating income of 26.6% of revenue, and net income of $515 million, or $3.43 per diluted share, for the quarter ended December 29, 2019 (the “December 2019 quarter”).

Non-GAAP Financial Results

For the March 2020 quarter, non-GAAP gross margin was $1,160 million, or 46.3% of revenue, non-GAAP operating expenses were $486 million, non-GAAP operating income was 26.9% of revenue, and non-GAAP net income was $590 million, or $3.98 per diluted share. This compares to non-GAAP gross margin of $1,181 million, or 45.7% of revenue, non-GAAP operating expenses of $481 million, non-GAAP operating income of 27.1% of revenue, and non-GAAP net income of $602 million, or $4.01 per diluted share, for the December 2019 quarter.

“Extraordinary efforts by Lam’s global teams helped to mitigate the operational impact of the COVID-19 pandemic, resulting in solid financial performance in the March quarter,” said Tim Archer, Lam Research’s President and Chief Executive Officer. “While there is limited visibility to near-term macroeconomic conditions and industry supply chain recovery, customer demand for our equipment remains strong. We believe in the long-term resiliency of the semiconductor industry and are focused on providing innovative technology to our customers and positioning Lam for outperformance as industry conditions normalize.”

---

Balance Sheet and Cash Flow Results

Cash and cash equivalents, short-term investments, and restricted cash and investments balances increased to $5.6 billion at the end of the March 2020 quarter compared to $4.9 billion at the end of the December 2019 quarter. This increase was primarily the result of a $1.25 billion draw down on the Company's revolving credit facility and $541.4 million of cash generated from operating activities. These sources of cash were partially offset by $617.6 million of principal payments on debt; $245.4 million of share repurchases, including net share settlement on employee stock-based compensation; $163.5 million of dividends paid to stockholders; and $51.4 million of capital expenditures.

Revenue

The geographic distribution of revenue during the March 2020 quarter is shown in the following table:

Region	Revenue
China	32%
Korea	23%
Taiwan	21%
Japan	10%
United States	9%
Europe	3%
Southeast Asia	2%

The following table presents revenue disaggregated between system and customer support-related revenue:

	Three Months Ended				Nine Months Ended
	March 29, <br>2020		March 31, <br>2019		March 29, <br>2020		March 31, <br>2019
	(In thousands)
System revenue	$	1,647,560	$	1,612,382	$	4,759,881	$	4,880,731
Customer support-related revenue and other	856,065		826,666		2,492,991		2,411,681
	$	2,503,625	$	2,439,048	$	7,252,872	$	7,292,412

System revenue includes sales of new leading-edge equipment in deposition, etch and clean markets.

Customer support-related revenue includes sales of customer service, spares, upgrades, and non-leading-edge equipment from our Reliant product line.

Use of Non-GAAP Financial Results

In addition to U.S. GAAP results, this press release also contains non-GAAP financial results. The Company’s non-GAAP results for both the March 2020 and December 2019 quarters exclude amortization related to intangible assets acquired through business combinations, amortization of note discounts, and income tax expense (benefit) of non-GAAP items. Additionally, the March 2020 quarter non-GAAP results exclude the effects of elective deferred compensation-related assets and liabilities. To enhance the comparability relative to the prior period, the Company has included reconciliation of both the originally-reported December 2019 quarter non-GAAP results, and recast December 2019 quarter non-GAAP results that conform to the current presentation with respect to the effects of elective deferred compensation-related assets and liabilities, in the reconciliation tables at the end of this press release. The March 2020 quarter non-GAAP results also exclude the income tax benefit on conclusion of certain tax matters related to a prior business combination; and the December 2019 quarter non-GAAP results exclude the cumulative income tax benefit reversal due to the Ninth Circuit decision to deny a rehearing of the Altera stock-based compensation case.

Management uses non-GAAP gross margin, operating expense, operating income, operating income as a percentage of revenue, net income, and net income per diluted share to evaluate the Company’s operating and financial results. The Company believes the presentation of non-GAAP results is useful to investors for analyzing business trends and comparing performance to prior periods, along with enhancing investors’ ability to view the Company’s results from management’s perspective. Tables presenting reconciliations of non-GAAP results to U.S. GAAP results are included at the end of this press release and on the Company’s website at http://investor.lamresearch.com.

---

Caution Regarding Forward-Looking Statements

Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to, but are not limited to: the impact of the COVID-19 outbreak on our operations and financial results; macroeconomic conditions; the status of the industry supply chain; customer demand for our equipment; industry conditions; the long–term resiliency of the semiconductor industry; the relevance of our technology to our customers; our positioning within the industry; and our ability to outperform. Some factors that may affect these forward-looking statements include: the severity, magnitude and duration of the COVID–19 pandemic (and the related governmental, public health, business and community responses to it), and their impacts on our business, results of operations and financial condition, are evolving and are highly uncertain and unpredictable; business, political and/or regulatory conditions in the consumer electronics industry, the semiconductor industry and the overall economy may deteriorate or change; the actions of our customers and competitors may be inconsistent with our expectations; and widespread outbreaks of illness may impact our operations and revenue in affected areas; as well as the other risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the Risk Factors described in our annual report on Form 10–K for the fiscal year ended June 30, 2019, our quarterly reports on Form 10–Q for the fiscal quarters ended September 29, 2019 and December 29, 2019, and our current report of Form 8–K dated April 22, 2020. These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary from expectations in a material way. The Company undertakes no obligation to update the information or statements made in this release.

About Lam Research

Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. As a trusted, collaborative partner to the world’s leading semiconductor companies, we combine superior systems engineering capability, technology leadership, and unwavering commitment to customer success to accelerate innovation through enhanced device performance. In fact, today, nearly every advanced chip is built with Lam technology. Lam Research (Nasdaq: LRCX) is a FORTUNE 500® company headquartered in Fremont, Calif., with operations around the globe. Learn more at www.lamresearch.com. (LRCX-F)

Consolidated Financial Tables Follow.

---

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data and percentages)

(unaudited)

	Three Months Ended									Nine Months Ended
	March 29, <br>2020			December 29, <br>2019			March 31, <br>2019			March 29, <br>2020			March 31, <br>2019
Revenue	$	2,503,625		$	2,583,501		$	2,439,048		$	7,252,872		$	7,292,412
Cost of goods sold	1,336,618			1,403,857			1,364,711			3,924,511			4,014,844
Gross margin	1,167,007			1,179,644			1,074,337			3,328,361			3,277,568
Gross margin as a percent of revenue	46.6		%	45.7		%	44.0		%	45.9		%	44.9		%
Research and development	307,914			318,861			318,514			913,602			895,742
Selling, general and administrative	164,979			174,272			190,306			496,679			534,179
Total operating expenses	472,893			493,133			508,820			1,410,281			1,429,921
Operating income	694,114			686,511			565,517			1,918,080			1,847,647
Operating income as a percent of revenue	27.7		%	26.6		%	23.2		%	26.4		%	25.3		%
Other (expense) income, net	(64,619		)	(13,924		)	20,532			(91,271		)	(10,494		)
Income before income taxes	629,495			672,587			586,049			1,826,809			1,837,153
Income tax expense	(54,714		)	(158,077		)	(38,659		)	(271,729		)	(187,548		)
Net income	$	574,781		$	514,510		$	547,390		$	1,555,080		$	1,649,605
Net income per share:
Basic	$	3.96		$	3.57		$	3.62		$	10.75		$	10.72
Diluted	$	3.88		$	3.43		$	3.47		$	10.39		$	10.20
Number of shares used in per share calculations:
Basic	145,301			143,987			151,201			144,654			153,891
Diluted	148,165			150,097			157,849			149,648			161,683
Cash dividend declared per common share	$	1.15		$	1.15		$	1.10		$	3.45		$	3.30

---

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

	March 29, <br>2020		December 29, <br>2019		June 30, <br>2019
	(unaudited)		(unaudited)		(1)
ASSETS
Cash and cash equivalents	$	3,961,586	$	3,035,887	$	3,658,219
Investments	1,431,550		1,647,867		1,772,984
Accounts receivable, net	2,191,070		2,030,490		1,455,522
Inventories	1,674,740		1,528,620		1,540,140
Prepaid expenses and other current assets	149,839		212,101		133,544
Total current assets	9,408,785		8,454,965		8,560,409
Property and equipment, net	1,048,619		1,047,254		1,059,077
Restricted cash and investments	254,155		253,907		255,177
Goodwill and intangible assets	1,666,732		1,677,940		1,701,547
Other assets	560,344		480,056		425,123
Total assets	$	12,938,635	$	11,914,122	$	12,001,333
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt and finance lease obligations	$	42,407	$	632,292	$	667,131
Other current liabilities	2,063,254		1,933,209		1,704,519
Total current liabilities	2,105,661		2,565,501		2,371,650
Long-term debt and finance lease obligations	5,043,931		3,786,067		3,822,768
Income taxes payable	889,287		872,778		892,790
Other long-term liabilities	350,603		272,043		190,821
Total liabilities	8,389,482		7,496,389		7,278,029
Temporary equity, convertible notes	11,546		38,304		49,439
Stockholders’ equity (2)	4,537,607		4,379,429		4,673,865
Total liabilities and stockholders’ equity	$	12,938,635	$	11,914,122	$	12,001,333
(1)	Derived from audited financial statements.
---	---
(2)	Common shares issued and outstanding were 145,156 as of March 29, 2020, 142,462 as of December 29, 2019, and 144,433 as of June 30, 2019.

---

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, unaudited)		Three Months Ended									Nine Months Ended
	March 29, <br>2020			December 29, <br>2019			March 31, <br>2019			March 29, <br>2020			March 31, <br>2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	574,781		$	514,510		$	547,390		$	1,555,080		$	1,649,605
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	67,248			65,530			82,274			197,442			243,873
Deferred income taxes	—			77,508			(12,401		)	74,516			(75,105		)
Equity-based compensation expense	47,414			45,725			53,240			136,044			142,389
Amortization of note discounts and issuance costs	1,361			1,575			2,861			4,611			5,137
Other, net	7,811			(327		)	(1,494		)	11,510			(646		)
Changes in operating assets and liabilities	(157,187		)	(396,593		)	260,951			(665,800		)	330,273
Net cash provided by operating activities	541,428			307,928			932,821			1,313,403			2,295,526
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures and intangible assets	(51,375		)	(62,054		)	(75,522		)	(152,685		)	(237,543		)
Net sale (purchase) of available-for-sale securities	211,159			(662,287		)	(931,380		)	339,350			(770,740		)
Other, net	9,988			(9,988		)	(1,269		)	(540		)	(5,288		)
Net cash provided by (used for) investing activities	169,772			(734,329		)	(1,008,171		)	186,125			(1,013,571		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on debt	(617,637		)	(17,987		)	(30,225		)	(664,589		)	(116,496		)
Net proceeds (repayments) from issuance of commercial paper	—			—			297,850			—			(61,754		)
Proceeds from borrowings on revolving credit facility	1,250,000			—			—			1,250,000			—
Proceeds from issuance of long-term debt, net of issuance costs	—			—			2,476,720			—			2,476,720
Treasury stock purchases	(245,433		)	(1,005,067		)	(934,637		)	(1,328,632		)	(2,672,051		)
Dividends paid	(163,510		)	(166,721		)	(171,196		)	(489,099		)	(513,475		)
Reissuance of treasury stock related to employee stock purchase plan	—			38,447			—			38,447			32,920
Proceeds from issuance of common stock	1,714			632			5,010			6,215			5,119
Other, net	328			—			—			328			(13,207		)
Net cash provided by (used for) financing activities	225,462			(1,150,696		)	1,643,522			(1,187,330		)	(862,224		)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(10,715		)	5,055			4,128			(9,853		)	(904		)
Net increase (decrease) in cash, cash equivalents, and restricted cash	925,947			(1,572,042		)	1,572,300			302,345			418,827
Cash, cash equivalents, and restricted cash at beginning of period	3,289,794			4,861,836			3,615,085			3,913,396			4,768,558
Cash, cash equivalents, and restricted cash at end of period	$	4,215,741		$	3,289,794		$	5,187,385		$	4,215,741		$	5,187,385

---

Non-GAAP Financial Summary

(in thousands, except percentages and per share data)

(unaudited)

	Three Months Ended
	March 29, <br>2020			December 29, <br>2019
				(As Previously Presented)
Revenue	$	2,503,625		$	2,583,501
Gross margin	$	1,159,981		$	1,181,271
Gross margin as percentage of revenue	46.3		%	45.7		%
Operating expenses	$	486,494		$	480,776
Operating income	$	673,487		$	700,495
Operating income as a percentage of revenue	26.9		%	27.1		%
Net income	$	590,359		$	601,810
Net income per diluted share	$	3.98		$	4.01
Shares used in per share calculation - diluted	148,165			150,097

Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income

(in thousands, except per share data)

(unaudited)

	Three Months Ended
	March 29,<br><br>2020			December 29, <br>2019			December 29, <br>2019
				(As Previously Presented)			(As Adjusted)
U.S. GAAP net income	$	574,781		$	514,510		$	514,510
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations - cost of goods sold	1,627			1,627			1,627
(Gain) loss on elective deferred compensation ("EDC") - related liability - cost of goods sold	(8,653		)	—			3,587
(Gain) loss on EDC - related liability - research and development	(15,575		)	—			6,456
Amortization related to intangible assets acquired through certain business combinations - selling, general and administrative	12,357			12,357			12,357
(Gain) loss on EDC - related liability - selling, general and administrative	(10,383		)	—			4,304
Amortization of note discounts - other expense, net	953			1,158			1,158
Loss (gain) on EDC - related asset - other expense, net	33,828			—			(14,129		)
Net income tax expense (benefit) on non-GAAP items	1,700			(2,358		)	(4,029		)
Income tax benefit on the conclusion of certain tax matters	(276		)	—			—
Cumulative income tax benefit reversal due to a court ruling	—			74,516			74,516
Non-GAAP net income	$	590,359		$	601,810		$	600,357
Non-GAAP net income per diluted share	$	3.98		$	4.01		$	4.00
U.S. GAAP net income per diluted share	$	3.88		$	3.43		$	3.43
U.S. GAAP and non-GAAP number of shares used for per diluted share calculation	148,165			150,097			150,097

---

Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income

(in thousands, except percentages)

(unaudited)

	Three Months Ended
	March 29, <br>2020			December 29, <br>2019			December 29,<br><br>2019
				(As Previously Presented)			(As Adjusted)
U.S. GAAP gross margin	$	1,167,007		$	1,179,644		1,179,644
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations	1,627			1,627			1,627
(Gain) loss on EDC-related liability	(8,653		)	—			3,587
Non-GAAP gross margin	$	1,159,981		$	1,181,271		$	1,184,858
U.S. GAAP gross margin as a percentage of revenue	46.6		%	45.7		%	45.7		%
Non-GAAP gross margin as a percentage of revenue	46.3		%	45.7		%	45.9		%
U.S. GAAP operating expenses	$	472,893		$	493,133		$	493,133
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations	(12,357		)	(12,357		)	(12,357		)
Gain (loss) on EDC-related liability	25,958			—			(10,760		)
Non-GAAP operating expenses	$	486,494		$	480,776		$	470,016
U.S. GAAP operating income	$	694,114		$	686,511		$	686,511
Non-GAAP operating income	$	673,487		$	700,495		$	714,842
U.S. GAAP operating income as percent of revenue	27.7		%	26.6		%	26.6		%
Non-GAAP operating income as a percent of revenue	26.9		%	27.1		%	27.7		%

Lam Research Corporation Contacts:

Tina Correia, Investor Relations, phone: 510-572-1615, e-mail: investor.relations@lamresearch.com